source
- Chinese partnerships are becoming the pharma industry's new tax inversion strategyThe article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…
- BioCryst to shut internal drug discovery and close Alabama research siteBioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…